News
MHLW (Japan) approves Wegovy from Novo Nordisk to treat Obesity
Wegovy (semaglutide once weekly injection),from Novo Nordisk, a GLP-1 receptor agonist that contains the same API as the diabetes treatments Ozempic (injection) and Rybelsus (tablet)
It was approved by MHLW for an indication of “obesity,” but it will only be used in “patients with hypertension, dyslipidemia, or type 2 diabetes who have not responded adequately to diet and exercise therapy” and have “a BMI of at least 27 kg/m2 and at least two obesity-related health disorders” or “a BMI of at least 35 kg/m2.”
Condition: Obesity
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.